Helsinki, Finland

Nina Wickstrand




Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 38(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inventor Spotlight: Nina Wickstrand

Introduction

Nina Wickstrand is a notable inventor based in Helsinki, Finland. She has made significant contributions to the field of biotechnology, particularly through her work involving beta-lactamases, a critical enzyme for combating antibiotic resistance. With one patent to her name, Wickstrand is an emerging figure within the innovation landscape.

Latest Patents

Wickstrand's patent, titled "Modified beta-lactamase and method for its preparation," focuses on the targeted post-translational modification of metallo-beta-lactamase. This innovation involves truncation and insertion of a dipeptide at the amino terminal end, aiming to reduce amino terminal heterogeneity in recombinant DNA production systems. The resulting protein, K-T-E-βBL, is subsequently modified by host proteases into E-βBL. This novel enzyme shows promise in pharmaceutical formulations, particularly as a treatment to alleviate antibiotic-induced adverse effects in patients using beta-lactam antibiotics.

Career Highlights

Nina Wickstrand is currently employed by Ipsat Therapies Oy, where she continues her research and development efforts. Her work exemplifies the intersection of academic inquiry and practical application in the pharmaceutical industry, allowing for significant advancements in antibiotic therapy and patient care.

Collaborations

Throughout her career, Wickstrand has collaborated with talented colleagues such as Susanna Kääriäinen and Pertti Koski. These partnerships have been integral in advancing her research and bringing innovative solutions to the market.

Conclusion

Nina Wickstrand's contributions to biotechnology through her innovative patent reflect her dedication to addressing pressing issues in medicine. Her work not only enhances our understanding of beta-lactamases but also holds potential for improving patient outcomes in antibiotic treatments. As she continues her work with Ipsat Therapies Oy, Nina is poised to make even more significant strides in her field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…